ライフサイエンスコーパス: hepatocellular carcinoma

1 ier to current immuno-oncologic therapies in hepatocellular carcinoma.

2 trahepatic hyperdensities, as well as a 3 cm hepatocellular carcinoma.

3 ab (anti-VEGF) in patients with unresectable hepatocellular carcinoma.

4 n attractive approach for chemoprevention of hepatocellular carcinoma.

5 HBV) is a leading cause of liver failure and hepatocellular carcinoma.

6 ct against IRI and IRI-induced metastasis of hepatocellular carcinoma.

7 sue which was histologically consistent with hepatocellular carcinoma.

8 se to the development of liver cirrhosis and hepatocellular carcinoma.

9 clinical spectrum ranging from steatosis to hepatocellular carcinoma.

10 development of cirrhosis, liver failure, and hepatocellular carcinoma.

11 fficacious in the treatment of patients with hepatocellular carcinoma.

12 se and as a potential therapeutic target for hepatocellular carcinoma.

13 hepatic malignancy such as hepatoblastoma or hepatocellular carcinoma.

14 an progress to cirrhosis, liver failure, and hepatocellular carcinoma.

15 ocol while pSTAT3 expression was detected in hepatocellular carcinoma.

16 erum sodium score was 18 (14-22); and 37 had hepatocellular carcinoma.

17 a biomarker-selected patient population with hepatocellular carcinoma.

18 ted HSCs in fibrotic tissues associated with hepatocellular carcinoma.

19 of pyruvate into the mitochondria, promoting hepatocellular carcinoma.

20 non-coding RNA (lncRNA) which is induced in hepatocellular carcinoma.

21 gressive liver disease and ultimately led to hepatocellular carcinoma.

22 antiviral therapy vs no therapy with risk of hepatocellular carcinoma.

23 ith rapid progression to liver cirrhosis and hepatocellular carcinoma.

24 +/- 0.01 %ID/g), limiting its application in hepatocellular carcinoma.

25 n, including 497 with cirrhosis and 113 with hepatocellular carcinoma.

26 gallstone cholangitis and a newly diagnosed hepatocellular carcinoma.

27 n promotes hepatocyte growth and progress to hepatocellular carcinoma.

28 er Disease score 6-29) were enrolled, 26 had hepatocellular carcinoma.

29 hronic viral hepatitis, liver cirrhosis, and hepatocellular carcinoma.

30 and pembrolizumab for treatment of advanced hepatocellular carcinoma.

31 sease: cirrhosis, hepatic decompensation, or hepatocellular carcinoma.

32 ersible damage to the liver and, ultimately, hepatocellular carcinomas.

33 a: 17 had colorectal liver metastases, 1 had hepatocellular carcinoma, 1 had mass-forming cholangioca

34 y included 6 patients (melanoma, 1; lung, 4; hepatocellular carcinoma, 1).

35 included colorectal liver metastases (69%), hepatocellular carcinoma (18%), non-colorectal liver met

36 growth of Clostridium difficile(1), promote hepatocellular carcinoma(2) and modulate host metabolism

37 ard ratio [HR], 0.40 [95% CI, 0.28-0.56) and hepatocellular carcinoma (20 studies, n = 84 491; pooled

38 m can be used to predict viable or nonviable hepatocellular carcinoma after ablation.

39 rumab compared with placebo in patients with hepatocellular carcinoma and alpha-fetoprotein concentra

40 acy of ramucirumab in patients with advanced hepatocellular carcinoma and alpha-fetoprotein concentra

41 To test this hypothesis, HUH-7 hepatocellular carcinoma and AML12 normal hepatocytes we

42 We present an unusual case of a patient with hepatocellular carcinoma and biliary invasion, who had h

43 e initial findings to pre-clinical models of hepatocellular carcinoma and breast cancer, we discovere

44 nificantly associated with increased risk of hepatocellular carcinoma and death (P < 0.01) but not de

45 d agents in trials of patients with advanced hepatocellular carcinoma and discuss the future of these

46 ty attributed to decompensated cirrhosis and hepatocellular carcinoma and examined the population-lev

47 nts, partial grafts, malignancies other than hepatocellular carcinoma and fulminant hepatitis.

48 ual tests on laboratory mice with inoculated hepatocellular carcinoma and in clinical conditions on p

49 Patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein

50 Integrative comparison of cHCC-ICC with hepatocellular carcinoma and intrahepatic cholangiocarci

51 een benign and malignant lesions, especially hepatocellular carcinoma and liver metastasis, and the s

52 egression modeling, we estimated the risk of hepatocellular carcinoma and liver-related mortality, ac

53 ssociated with a significantly lower risk of hepatocellular carcinoma and lower liver-related mortali

54 Moreover, CNApp reproduces recurrent CNAs in hepatocellular carcinoma and predicts colon cancer molec

55 broader background information on pediatric hepatocellular carcinoma and rationale for recommendatio

56 sis (1.77 [1.00-3.14], P = 0.05), history of hepatocellular carcinoma and/or liver transplantation (7

57 re, LRPPRC suppresses genome instability and hepatocellular carcinomas and promotes survivals in mice

58 LRPPRC knockout mice develop more and larger hepatocellular carcinomas and survive a shorter lifespan

59 c applications in hepatocyte growth biology, hepatocellular carcinoma, and HCV pathogenesis.

60 inhibition protects against prostate cancer, hepatocellular carcinoma, and metabolic derangements ind

61 htly raised aminotransferases; cirrhosis and hepatocellular carcinoma are rare.

62 Hepatocellular carcinoma as a complication is linked to

63 The permanent activation of hepatocellular carcinoma-associated proto-oncogenes such

64 Adults with cirrhosis awaiting LT without hepatocellular carcinoma at nine LT centers in the Unite

65 ce the risk of progressive liver disease and hepatocellular carcinoma but is often administered for a

66 tality rates from liver disease (cirrhosis + hepatocellular carcinoma), but data are lacking at the l

67 HuH7 human hepatocellular carcinoma cells containing CRISPR-Cas9 ge

68 signature was enriched in a subset of human hepatocellular carcinomas characterized by comparatively

69 The study included five cohorts, and the two hepatocellular carcinoma cohorts, groups A and F, are de

70 have a higher mortality risk and more severe hepatocellular carcinoma compared to HCV monoinfected pa

71 minations for both the test data set and the hepatocellular carcinoma data set.

72 g patients with normal liver, cirrhosis, and hepatocellular carcinoma derived from multiple etiologic

73 re on mortality, hepatic decompensation, and hepatocellular carcinoma development in a large national

74 r disease, incorporating serum sodium score, hepatocellular carcinoma diagnosis, presence of ascites,

75 s including ascites, hepatic encephalopathy, hepatocellular carcinoma, esophageal variceal bleed, and

76 t (J-C), becomes the driver of fibrolamellar hepatocellular carcinoma (FL-HCC).

77 d-line setting for patients with an advanced hepatocellular carcinoma from the German statutory healt

78 ts undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC) (exploratory analysis of

79 becular-massive" (MTM) histologic subtype of hepatocellular carcinoma (HCC) (MTM-HCC) represents an a

80 iver complication -hepatic decompensation or hepatocellular carcinoma (HCC) - or requiring liver tran

81 e principal histologic type of liver cancer, hepatocellular carcinoma (HCC) accounts for the great ma

82 e are conflicting data regarding the risk of hepatocellular carcinoma (HCC) after direct-acting antiv

83 e algorithm (TRA) is used to assess presumed hepatocellular carcinoma (HCC) after local-regional ther

84 Early recurrence of hepatocellular carcinoma (HCC) after surgical resection

85 HCV) and advanced fibrosis remain at risk of hepatocellular carcinoma (HCC) after sustained viral res

86 etabolic traits on the risk of cirrhosis and hepatocellular carcinoma (HCC) among patients with NAFLD

87 re 87.1%, 71.8%, and 62.8% for patients with hepatocellular carcinoma (HCC) and 87.5%, 70.0% and 70.0

88 Hepatobiliary cancers which include hepatocellular carcinoma (HCC) and biliary tract cancers

89 management of primary liver cancers such as hepatocellular carcinoma (HCC) and cholangiocarcinoma (C

90 e examined incidence rates for cirrhosis and hepatocellular carcinoma (HCC) and conducted cause-speci

91 ate that MTR4 is frequently overexpressed in hepatocellular carcinoma (HCC) and is an independent dia

92 l vein thrombosis (PVT) occurs frequently in hepatocellular carcinoma (HCC) and is often diagnosed in

93 patients based on the level of suspicion for hepatocellular carcinoma (HCC) and overall malignancy.

94 Median survival in patients with hepatocellular carcinoma (HCC) and portal vein tumor thr

95 al characteristics of ESLD from cirrhosis or hepatocellular carcinoma (HCC) and the performance of as

96 rly 80% of cirrhotic patients diagnosed with hepatocellular carcinoma (HCC) are not eligible for surg

97 Prevention and treatment options for hepatocellular carcinoma (HCC) are presently limited, un

98 isk-stratification systems for patients with hepatocellular carcinoma (HCC) are required to improve t

99 ioembolization (yttrium-90 [Y90]) is used in hepatocellular carcinoma (HCC) as a bridging as well as

100 w the applicability of our approach, we used hepatocellular carcinoma (HCC) as a model system.

101 th chronic liver disease have lower rates of hepatocellular carcinoma (HCC) as compared to men; it is

102 er transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) because of the potential

103 cation is extremely complex in patients with hepatocellular carcinoma (HCC) because this neoplasm ari

104 splant (LT) prioritization for patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC

105 f intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) by noninvasive methods re

106 rates according to screening guidelines for hepatocellular carcinoma (HCC) by OcC and OvC status.

107 from healthy and HBV-infected donors toward hepatocellular carcinoma (HCC) cells containing integrat

108 Here we show that activated AKT in human hepatocellular carcinoma (HCC) cells phosphorylates cyto

109 We examined hepatocellular carcinoma (HCC) development in alcohol We

110 s with normal liver function and facilitates hepatocellular carcinoma (HCC) development, representing

111 ase SULF2 has been associated with increased hepatocellular carcinoma (HCC) growth and poor patient s

112 There are limited data on hepatocellular carcinoma (HCC) growth patterns, particul

113 eached epidemic proportions and in parallel, hepatocellular carcinoma (HCC) has become one of the fas

114 Among them, an increased risk of hepatocellular carcinoma (HCC) has been registered.

115 Hepatocellular carcinoma (HCC) has high relapse and low

116 To date, genomic analyses of hepatocellular carcinoma (HCC) have been limited to earl

117 d SVR on all-cause mortality and on incident hepatocellular carcinoma (HCC) in 15,059 hepatitis C vir

118 d be used as a marker for early detection of hepatocellular carcinoma (HCC) in different etiologies,

119 t of HIV infection on the risk of developing hepatocellular carcinoma (HCC) in HCV-infected patients

120 association between diabetes and the risk of hepatocellular carcinoma (HCC) in NASH patients with cir

121 Genetic factors and steatosis predispose to hepatocellular carcinoma (HCC) in patients with chronic

122 C virus (HCV) infection is the main cause of hepatocellular carcinoma (HCC) in the United States (US)

123 viral infections are major risk factors for hepatocellular carcinoma (HCC) in the United States and

124 Mongolia has the highest incidence of hepatocellular carcinoma (HCC) in the world, but its cau

125 critical role in liver tissue damage and in hepatocellular carcinoma (HCC) initiation and progressio

126 CSCs) are considered as main players for the hepatocellular carcinoma (HCC) initiation, metastasis, d

127 Hepatocellular carcinoma (HCC) is a highly fatal disease

128 Hepatocellular carcinoma (HCC) is a liver tumor that usu

129 Hepatocellular carcinoma (HCC) is a most deadly malignan

130 Hepatocellular carcinoma (HCC) is an aggressive malignan

131 Hepatocellular carcinoma (HCC) is an increasingly common

132 Hepatocellular carcinoma (HCC) is clearly age-related an

133 Hepatocellular carcinoma (HCC) is difficult to detect, c

134 ions in cancer driver genes in patients with hepatocellular carcinoma (HCC) is highly diverse, which

135 The molecular background of hepatocellular carcinoma (HCC) is highly heterogeneous,

136 The risk for hepatocellular carcinoma (HCC) is increased in acute hep

137 Hepatocellular carcinoma (HCC) is increasing in frequenc

138 The gender disparity of hepatocellular carcinoma (HCC) is most striking in hepat

139 The incidence of hepatocellular carcinoma (HCC) is on the rise worldwide.

140 Hepatocellular carcinoma (HCC) is one of most common can

141 Hepatocellular Carcinoma (HCC) is one of the most lethal

142 The pathogenesis of hepatocellular carcinoma (HCC) is poorly understood, but

143 Hepatocellular carcinoma (HCC) is the fourth leading cau

144 Hepatocellular carcinoma (HCC) is the most common cause

145 Hepatocellular carcinoma (HCC) is the most common form o

146 Hepatocellular carcinoma (HCC) is the most common primar

147 Hepatocellular carcinoma (HCC) is the second leading cau

148 Hepatocellular carcinoma (HCC) is the second most common

149 Hepatocellular carcinoma (HCC) is the sixth most common

150 Hepatocellular carcinoma (HCC) is the third most frequen

151 in patients with hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) listed for liver transpla

152 tor (FGFR) expression in 17.7% (11 of 62) of hepatocellular carcinoma (HCC) models.

153 associated with the overall survival (OS) of hepatocellular carcinoma (HCC) patients treated with tra

154 rapy (LRT) in a large, multicenter cohort of hepatocellular carcinoma (HCC) patients undergoing liver

155 Through analysis of tumor tissues from hepatocellular carcinoma (HCC) patients, we were able to

156 on between mouse liver development and human hepatocellular carcinoma (HCC) proteomic profiles reveal

157 ce after transarterial embolization (TAE) of hepatocellular carcinoma (HCC) provides a compelling cli

158 Currently, no surveillance guidelines for hepatocellular carcinoma (HCC) recurrence after liver tr

159 Sorafenib (SOR) is currently used for hepatocellular carcinoma (HCC) recurring after liver tra

160 ht and sex on liver transplantation (LT) for hepatocellular carcinoma (HCC) remains unclear.

161 Hepatocellular carcinoma (HCC) represents the sixth most

162 It is unclear if hepatocellular carcinoma (HCC) risk declines over time a

163 Hepatocellular carcinoma (HCC) surveillance is associate

164 Hepatocellular carcinoma (HCC) surveillance is associate

165 PRMT6) regulates aerobic glycolysis in human hepatocellular carcinoma (HCC) through nuclear relocaliz

166 itional expression of MYC and Twist1 enables hepatocellular carcinoma (HCC) to metastasize in >90% of

167 LT) in patients who achieved down-staging of hepatocellular carcinoma (HCC) to Milan criteria.

168 ath and the resulting cell debris stimulates hepatocellular carcinoma (HCC) tumor growth via an "eico

169 ng antiviral (DAA) therapy for hepatitis and hepatocellular carcinoma (HCC) with regard to HCC incide

170 atitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) worldwide.

171 sion and negatively with Keap1 expression in hepatocellular carcinoma (HCC) xenografts and specimens.

172 ression plays key roles in tumors, including hepatocellular carcinoma (HCC), a malignancy with no eff

173 arkers in human alcoholic hepatitis (AH) and hepatocellular carcinoma (HCC), and mouse liver tumor in

174 n about the mutational landscape of advanced hepatocellular carcinoma (HCC), and predictive biomarker

175 ence is the major cause of poor prognosis in hepatocellular carcinoma (HCC), however, the underlying

176 Owing to the marked sexual dimorphism of hepatocellular carcinoma (HCC), sex hormone receptor sig

177 Hepatocellular carcinoma (HCC), the most common type of

178 pite significant progression in the study of hepatocellular carcinoma (HCC), the role of the proteaso

179 , this difference is predominantly driven by hepatocellular carcinoma (HCC), which accounts for 75% o

180 , this difference is predominantly driven by hepatocellular carcinoma (HCC), which accounts for 75% o

181 atitis B virus (HBV) to increase the risk of hepatocellular carcinoma (HCC), which might be explained

182 r recurrence after liver transplantation for hepatocellular carcinoma (HCC), with and without hypothe

183 liver complication-hepatic decompensation or hepatocellular carcinoma (HCC)-or requiring liver transp

184 We report a covalent chemistry-based hepatocellular carcinoma (HCC)-specific extracellular ve

185 proposed to contribute to the progression of hepatocellular carcinoma (HCC).

186 r disease which often leads to cirrhosis and hepatocellular carcinoma (HCC).

187 h a greater risk of liver cirrhosis (LC) and hepatocellular carcinoma (HCC).

188 are deregulated in disease states, including hepatocellular carcinoma (HCC).

189 ha (ERalpha) might impact the progression of hepatocellular carcinoma (HCC).

190 RT) over sorafenib in patients with advanced hepatocellular carcinoma (HCC).

191 ction is one of the major causal factors for hepatocellular carcinoma (HCC).

192 ncreased fibrosis staging and development of hepatocellular carcinoma (HCC).

193 rate during compensatory regeneration and in hepatocellular carcinoma (HCC).

194 o rescue (FTR) following liver resection for hepatocellular carcinoma (HCC).

195 n relation to the morbidity in patients with hepatocellular carcinoma (HCC).

196 granted to liver transplant candidates with hepatocellular carcinoma (HCC).

197 disease influences the risk of cirrhosis and hepatocellular carcinoma (HCC).

198 (HBV)-the major cause of liver cirrhosis and hepatocellular carcinoma (HCC).

199 rease the risk of various cancers, including hepatocellular carcinoma (HCC).

200 adioembolization (TARE) in participants with hepatocellular carcinoma (HCC).

201 down-regulated in human sorafenib-resistant hepatocellular carcinoma (HCC).

202 for developing alcohol-related cirrhosis and hepatocellular carcinoma (HCC).

203 liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC).

204 H), potentially progressing to cirrhosis and hepatocellular carcinoma (HCC).

205 on a separate data set of 2369 patients with hepatocellular carcinoma (HCC).

206 inflammation to cirrhosis, liver failure or hepatocellular carcinoma (HCC).

207 utcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC).

208 oholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC).

209 lycan changes in human serum associated with hepatocellular carcinoma (HCC).

210 B virus (HBV) infection is a risk factor for hepatocellular carcinoma (HCC).

211 nase inhibitor approved for the treatment of hepatocellular carcinoma (HCC).

212 have revealed multiple molecular subtypes of hepatocellular carcinoma (HCC).

213 ligand B7 homolog 6 (B7-H6) in patients with hepatocellular carcinoma (HCC).

214 umerous malignancies including viral-derived hepatocellular carcinoma (HCC).

215 (lncRNAs) are often aberrantly expressed in Hepatocellular Carcinoma (HCC).

216 PRMT1 regulates the tumor immune response in hepatocellular carcinoma (HCC).

217 of liver transplants (LT) are performed for hepatocellular carcinoma (HCC).

218 is strongly overexpressed in mouse and human hepatocellular carcinoma (HCC).

219 plays a critical role in the progression of hepatocellular carcinoma (HCC).

220 nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC).

221 ike phenotypes in diverse cancers, including hepatocellular carcinoma (HCC).

222 es and is associated with the development of hepatocellular carcinoma (HCC).

223 ciency virus (HIV) are at risk of developing hepatocellular carcinoma (HCC).

224 er injury is a risk factor for cirrhosis and hepatocellular carcinoma (HCC).

225 of liver function and a tumor suppressor in hepatocellular carcinoma (HCC).

226 ral major factors limit our understanding of hepatocellular carcinoma (HCC).

227 ivating mutations of beta-catenin itself [in hepatocellular carcinoma (HCC)].

228 Here, we devise a strategy for targeting hepatocellular carcinoma (HCC, one of the deadliest mali

229 Hepatocellular carcinomas (HCC) exhibit distinct promote

230 Interestingly, in hepatocellular-carcinoma (HCC) patients, a significant S

231 lication of process measures (i.e., rates of hepatocellular carcinoma [HCC] screening, endoscopic var

232 for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non-acquired immunodefi

233 g-term risks for liver-related events (i.e., hepatocellular carcinoma [HCC], hepatic decompensation,

234 Background Intermediate stage hepatocellular carcinomas (HCCs) are treated by inducing

235 Most hepatocellular carcinomas (HCCs) develop in patients wit

236 itors are effective in the treatment of some hepatocellular carcinomas (HCCs), but these tumors do no

237 In one-third of hepatocellular carcinomas (HCCs), cancer cells have muta

238 account for any differences by diagnosis of hepatocellular carcinoma, hepatitis C virus, nonalcoholi

239 besity and inflammation are risk factors for hepatocellular carcinoma, however, the role of Nod2 in o

240 P < 0.001) and rather weak in patients with hepatocellular carcinoma (HR, 1.003; P = 0.038).

241 sed risks of cholangiocarcinoma (HR, 28.46), hepatocellular carcinoma (HR, 21.00), pancreatic cancer

242 ed to activate FXR both in mice and in human hepatocellular carcinoma (Huh-7) cells.

243 nvestigated in an ectopic xenograft model of hepatocellular carcinoma in mice.

244 e (56)Fe ion irradiation on the formation of hepatocellular carcinoma in mice.

245 ubicin-loaded nanoparticles in patients with hepatocellular carcinoma in whom previous sorafenib ther

246 including bridging fibrosis, cirrhosis, and hepatocellular carcinoma, in this population.

247 were pooled NAFLD prevalence, incidence, and hepatocellular carcinoma incidence and overall mortality

248 s an option for sorafenib-resistant advanced hepatocellular carcinoma, increasing overall survival an

249 Microwave ablation in patients with hepatocellular carcinoma is a safety treatment modality

250 of aberrant MHC II in malignancy, including hepatocellular carcinoma, is also reviewed.

251 s of low-dose aspirin (<=160 mg) on incident hepatocellular carcinoma, liver-related mortality, and g

252 driver of growth and survival in a subset of hepatocellular carcinomas, making selective FGFR4 inhibi

253 -forming cholangiocarcinoma, and 1 had mixed hepatocellular carcinoma-mass-forming cholangiocarcinoma

254 egressed tumor growth in the xenograft human hepatocellular carcinoma mouse model.

255 We analyzed primary hepatocellular carcinoma (n = 10) and metastatic gastroi

256 nt incidentally detected second tumours were hepatocellular carcinoma (nine patients, 20% of 45 incid

257 Microwave ablation was applied to 42 hepatocellular carcinoma nodules in 31 patients.

258 olizumab alone in patients with unresectable hepatocellular carcinoma not previously treated with sys

259 control stage (benign) to the early stage of hepatocellular carcinoma on an eight-stage disease datas

260 patients underwent liver transplantation for hepatocellular carcinoma or adenoma.

261 ated with Hispanic race over NHW in cases of hepatocellular carcinoma or cholestatic liver disease.

262 Hepatocellular carcinomas (OR 0.319, 95% CI 0.107-0.949,

263 ning on clinical outcomes such as mortality, hepatocellular carcinoma, or cirrhosis.

264 excluding those listed for multiple organs, hepatocellular carcinoma, or living donor LT.

265 are in the second-line treatment of advanced hepatocellular carcinoma over a lifetime horizon.

266 Restoring mitochondrial function in human hepatocellular carcinomas overcomes cancer resistance.

267 Twenty-three hepatocellular carcinoma patients undergoing RE treatmen

268 t its complications, including cirrhosis and hepatocellular carcinoma, pharmacological interventions

269 ve androgen receptor splice variants promote hepatocellular carcinoma progression by regulating the e

270 (steatosis, steatohepatitis, cirrhosis, and hepatocellular carcinoma) recognized in human NAFLD when

271 mia, prostate cancer and hepatitis B-induced hepatocellular carcinoma, repeated infusions of these po

272 Hepatocellular carcinoma screening in NAFLD patients wit

273 lder recipients and especially patients with hepatocellular carcinoma seem to be less affected by an

274 safety of microwave ablation (MWA) in small hepatocellular carcinomas sized <= 3 cm, determine long-

275 cant morbidity and mortality from cirrhosis, hepatocellular carcinoma, solid organ malignancies, diab

276 osis helped identify macrotrabecular-massive hepatocellular carcinoma subtype with high specificity.

277 0; 95% confidence interval [CI], 0.78-0.82), hepatocellular carcinoma surveillance (HR, 0.92; 95% CI,

278 er Diseases criteria) confirmed unresectable hepatocellular carcinoma that was not amenable to curati

279 In human hepatocellular carcinoma, the presence of a migration-as

280 trospective review included 53 patients with hepatocellular carcinoma treated with radioembolization

281 umor response in locally advanced inoperable hepatocellular carcinoma treated with TARE.

282 tter overall survival and disease control in hepatocellular carcinoma treated with transarterial radi

283 population and appears to result in improved hepatocellular carcinoma treatment response.

284 rafenib versus Radioembolization in Advanced Hepatocellular Carcinoma trial.

285 ies, we demonstrate the use of ClonArch on a hepatocellular carcinoma tumor with ~280 sequencing biop

286 Treatment of hepatocellular carcinomas using our glypican-3 (GPC3)-ta

287 Adjusted 10-year cumulative probabilities of hepatocellular carcinoma, vascular events, and nonhepati

288 patients with NAFLD, the annual incidence of hepatocellular carcinoma was 1.8 cases per 1000 person-y

289 ow-up, the estimated cumulative incidence of hepatocellular carcinoma was 4.0% among aspirin users an

290 or each TA-allele, the risk of cirrhosis and hepatocellular carcinoma was reduced by 15% and 28%, res

291 y analysis was performed where patients with hepatocellular carcinoma were included.

292 codes of cirrhosis and without a history of hepatocellular carcinoma were included.

293 codes of cirrhosis and without a history of hepatocellular carcinoma were included.

294 ifferent gastrointestinal cancers, including hepatocellular carcinoma, which is currently undruggable

295 Adults without hepatocellular carcinoma who were on the liver transplan

296 Hepatocellular carcinoma with biliary ductal invasion is

297 Conclusion Hepatocellular carcinoma with nuclear factor E2-related

298 atients was not different from patients with hepatocellular carcinoma within Milan receiving exceptio

299 s study describes trends in the incidence of hepatocellular carcinoma within the Veterans Health Admi

300 chronic infection remains the major cause of hepatocellular carcinoma worldwide, with more than half